Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. | ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...

The Federal Trade Commission (FTC) has begun outlining its case against Edwards Lifesciences' proposed purchase of heart ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...